ExoBRID-E

¬¿¬Ü¬Ù¬à¬ã¬à¬Þ¬í ¬é¬Ö¬Ý¬à¬Ó¬Ö¬Ü¬Ñ

¬¹¬ä¬à ¬ä¬Ñ¬Ü¬à¬Ö ExoBRID-E?
  • ¬£ ¬Ü¬Ñ¬é¬Ö¬ã¬ä¬Ó¬Ö ¬ã¬í¬â¬î¬ñ, ¬Ü¬à¬ä¬à¬â¬à¬Ö ¬ã¬ä¬Ñ¬Ò¬Ú¬Ý¬Ú¬Ù¬Ú¬â¬å¬Ö¬ä ¬ï¬Ü¬Ù¬à¬ã¬à¬Þ¬í ¬Ó¬í¬ã¬à¬Ü¬à¬Û ¬é¬Ú¬ã¬ä¬à¬ä¬í ¬à¬ä 0,1 ¬Õ¬à 0,5% ¬â¬Ñ¬ã¬ä¬Ó¬à¬â¬Ñ ¬Ü¬å¬Ý¬î¬ä¬å¬â¬í ¬ã¬ä¬Ó¬à¬Ý¬à¬Ó¬í¬ç ¬Ü¬Ý¬Ö¬ä¬à¬Ü ¬ã ¬á¬à¬Þ¬à¬ë¬î¬ð ¬ä¬Ö¬ç¬ß¬à¬Ý¬à¬Ô¬Ú¬Ú ExoBRID,
  • ¬°¬ß ¬ã¬à¬Õ¬Ö¬â¬Ø¬Ú¬ä ¬Ò¬à¬Ý¬Ö¬Ö 400 ¬Ý¬Ú¬á¬Ú¬Õ¬à¬Ó, ¬Ò¬à¬Ý¬Ö¬Ö 600 ¬Þ¬²¬¯¬¬, ¬Ò¬à¬Ý¬Ö¬Ö 1000 ¬Ò¬Ö¬Ý¬Ü¬à¬Ó ¬Ú ¬æ¬Ñ¬Ü¬ä¬à¬â¬à¬Ó ¬â¬à¬ã¬ä¬Ñ ¬Ó ¬Ü¬Ñ¬é¬Ö¬ã¬ä¬Ó¬Ö ¬Ñ¬Ü¬ä¬Ú¬Ó¬ß¬í¬ç ¬Ú¬ß¬Ô¬â¬Ö¬Õ¬Ú¬Ö¬ß¬ä¬à¬Ó.
ExoBRID-E ¬©¬Ñ¬â¬å¬Ò¬Ö¬Ø¬ß¬Ñ¬ñ ¬â¬Ö¬Ô¬Ú¬ã¬ä¬â¬Ñ¬è¬Ú¬ñ ¬Ü¬à¬ã¬Þ¬Ö¬ä¬Ú¬é¬Ö¬ã¬Ü¬à¬Ô¬à ¬ã¬í¬â¬î¬ñ
ExoCoBio
  • Áٱ⼼Æ÷¹è¾ç¾×ÀÇ 0.5%ÀÇ °í¼øµµ ¿¢¼ÒÁ»¿¡ ÇǺΠº¼·ù¸¶ÀÌ¡ ¿ø·á¸¦ °áÇÕÇÏ¿© ź·Â°ú º¼·ù¸¶ÀÌ¡¿¡
  • ´õ¿í È¿°úÀûÀÌ°í ¾ÈÀüÇÑ Æ¯Ç㼺ºÐÀÔ´Ï´Ù.
ExoBRID-E Publication

Exosome, ¬ß¬à¬Ó¬í¬Û ¬Ò¬Ú¬à ¬Ü¬à¬Þ¬á¬à¬ß¬Ö¬ß¬ä ¬â¬Ö¬Ô¬Ö¬ß¬Ö¬â¬Ñ¬ä¬Ú¬Ó¬ß¬à¬Û ¬ï¬ã¬ä¬Ö¬ä¬Ú¬Ü¬Ú,
¬à¬Ò¬Ö¬ã¬á¬Ö¬é¬Ú¬Ó¬Ñ¬Ö¬ä ¬Ö¬ã¬ä¬Ö¬ã¬ä¬Ó¬Ö¬ß¬ß¬à¬Ö ¬Ù¬Õ¬à¬â¬à¬Ó¬î¬Ö ¬Ü¬à¬Ø¬Ú.

¬´¬Ö¬ç¬ß¬à¬Ý¬à¬Ô¬Ú¬ñ ExoBRID
  • ¬°¬á¬ä¬Ú¬Þ¬Ñ¬Ý¬î¬ß¬Ñ¬ñ ¬ä¬Ö¬ç¬ß¬à¬Ý¬à¬Ô¬Ú¬ñ ¬â¬Ñ¬Ù¬â¬Ñ¬Ò¬à¬ä¬Ü¬Ú ¬Ü¬à¬ã¬Þ¬Ö¬ä¬Ú¬é¬Ö¬ã¬Ü¬Ú¬ç ¬Ú¬ß¬Ô¬â¬Ö¬Õ¬Ú¬Ö¬ß¬ä¬à¬Ó ¬ß¬Ñ ¬à¬ã¬ß¬à¬Ó¬Ö ¬ï¬Ü¬Ù¬à¬ã¬à¬Þ ¬Ò¬Ú¬à¬Ô¬Ú¬Ò¬â¬Ú¬Õ¬ß¬í¬Þ ¬Þ¬Ö¬ä¬à¬Õ¬à¬Þ